British Journal of Clinical Pharmacology

Article	Citations
	61
Issue Information	58
Issue Highlights	56
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	55
Selected Abstracts from Pharmacology 2024	54
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	52
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	50
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	49
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	49
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	48
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	48
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	48
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	47
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	46
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	42
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	40
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	39
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	39
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	36
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	36
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	36
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	36
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	36
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	35
Triple antithrombotic therapy and dual therapy – What is the evidence base?	34

Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	34
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	34
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	33
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	33
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	32
Antidepressants are not safe during pregnancy and in women of child‐bearing age	32
Pregabalin poisoning: Evaluation of dose‐toxicity relationship	32
Comparison of a polypharmacy‐based scale with Charlson comorbidity index to predict 6‐month mortality in chronic complex patients after an ED visit	30
Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	29
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	29
Modelling the progression of illicit substance use patterns from real‐world evidence	29
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	29
Lemborexant levels in breast milk after single doses in healthy, lactating women	29
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	29
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	29
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	28
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	28
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	27
Potential drug–drug interactions when managing status epilepticus patients in intensive care: A cohort study	27
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings	27
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	27
Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database	26
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	25
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	25
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice	24
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self‐controlled case series study	24
	24
Issue Information	23
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations	23
Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study	23
Issue Highlights	23
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	23
Medication compliance aids unpackaged: A national survey	22
Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study	22
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach	21
The association between hormonal contraceptive use and glaucoma in women of reproductive age	21
Predicting outcomes for spinal muscular atrophy: When the diagnosis no longer means what it used to mean	21
The trajectory of pharmacometrics to support drug licensing and labelling	21
Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care	21
From statistical inference to machine learning: A paradigm shift in contemporary cardiovascular pharmacotherapy	21
A pharmacometrics model to define docetaxel target in early breast cancer	20
Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department	20
In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database	20
Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance	20
Coping with COVID: Preparing prescribers during the pandemic	20
Out‐of‐hospital cardiac arrest and differential risk of cardiac and non‐cardiac QT‐prolonging drugs in 37 000 cases	20
Long‐term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?	20
Hospital pharmacists' opinions on a risk prediction tool for medication‐related harm in older people	20
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper	20
Validation of self‐reported medication use applying untargeted mass spectrometry‐based metabolomics techniques in the Rhineland study	20

The effects of saffron (Crocus sativus L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes m	19
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach	19
Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023	19
Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients	19
Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis	19
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite	19
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant	19
Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods	18
	18
Performance of the ChatGPT large language model for decision support in community pharmacy	18
Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis	18
Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients	18
Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data	18
Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies	18
Management of serotonin syndrome (toxicity)	18
Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects	18
Spotlight commentary: Innovations in clinical trials	17
The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study	17
Issue Highlights	17
Correction	17
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis	17
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model	17
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis	17
Issue highlights	17
A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU	17
	17
Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis‐inspired systematic review	16
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy	16
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients	16
Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages	16
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021	16
Ethical concern regarding the UK PANORAMIC COVID‐19 trial	16
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system	16
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis	16
Challenging times: Delivering gene therapies and an opportunity for shared learning	16
Cabotegravir PopPK analysis of adults and adolescents living with HIV/at risk for HIV receiving prep	16
Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis	16
Association of renin–angiotensin–aldosterone system inhibition with Covid‐19 hospitalization and all‐cause mortality in the UK biobank	16
Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials	16
Do we become better prescribers after graduation: A 1‐year international follow‐up study among junior doctors	16
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation	16
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants	16
A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg	16
Epigenetic modifications in drug‐induced liver injury: A systematic review	16
Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection	16
Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis	16
Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning	15
Assessment and evaluation of prescribing competences: A systematic review and recommendations	15
Association of state‐level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia	15
Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model	15
Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach	15
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment	15
Physostigmine should be used more readily for antimuscarinic toxicity: CON	15
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	15
Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties	15
Challenge in treating COVID‐19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels	15
Precision medicine and theranostics using radiopharmaceuticals in oncology	15
Variability in the prevalence of inappropriate medication use among older adults: A review highlighting the importance of screening methods and database types	15
Sustainable medicines use in clinical practice: A clinical pharmacological view on eco‐pharmaco‐stewardship	15
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus	14
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers	14
Issue Highlights	14
Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus	14
Correction to “Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study”	14
Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing	14
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	14
Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats	14
Issue Information	14
Appraising the visibility, relevance and impacts of clinical pharmacology	14
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV	14
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	14
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report	14
Infliximab‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis	14
	14
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease	13
Pharmacoethics and pregnancy: Overcoming the therapeutic orphan stigma	13
A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects	13
Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis	13
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2	13
Risk of out‐of‐hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs	13

Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist	13
Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients	13
Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?	13
Paediatric and obstetrical pharmacology – Pushing the frontier forward	13
Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4	13
Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour	13
Risk of out‐of‐hospital cardiac arrest in antidepressant drug users	13
Beta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation	13
Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study	13
Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism	13
Issue Information	12
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study	12
Prescriptions of anti‐reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014–2022)	12
Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo‐controlled first‐in‐human study in healthy volunteers	12
Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders	12
Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis	12
Adherence levels and patterns for multiple cardiac medications prescribed to patients with incident atrial fibrillation events	12
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers	12
Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women	12
Sustainable medicines development and use: Our collective responsibility for action to mitigate the natural world crisis	12
Pro: Oximes should be used routinely in organophosphate poisoning	12
Changes in antiepileptic drug prescriptions over a decade in childbearing women in Lombardy region, Italy	12
Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales	12
Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan	12
Results of the first international quality control programme for oral targeted oncolytics	12
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples	12
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6	12
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration	12
	12
Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib	12
Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers	12
Para‐aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research	12
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis	12
Identification and comparison of sex‐specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED)	12
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam	12
Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review	12
Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients	12
Assessment of the influence of body fat indices on antihypertensive drug responses	12
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study	11
Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers	11
Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4‐methylaminoantipyrine	11
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin	11
Issue Information	11
Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium	11
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials	11
Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation	11
Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories	11
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions	11
Concentrations of psychoactive substances in blood samples from non‐fatal and fatal opioid overdoses	11
Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study	11
Safe and supportive prescribing in transgender and non‐binary patients with cancer	11
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation	11
The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer	11
Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people	11
Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia	11
Addition of direct oral anticoagulants to the World Health Organization model list of essential medicines for the treatment of atrial fibrillation: An African perspective	11
A population physiologically‐based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab	11
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients	11
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients	11
Local variation in low carbon footprint inhalers in pre‐COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact	11
Clinical pharmacology in adolescent transgender medicine	11
Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals	11
Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease	11
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols	11
Clinical validation of clinical decision support systems for medication review: A scoping review	11
Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings	11
Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne	11
‘Under pressure’: The role of therapeutic drug monitoring in the treatment of hypertension	10
Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database	10
Anthony Peck (1933–2021)	10
Implementability of opioid deprescribing interventions at transitions of care: A scoping review	10
Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy	10
Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam	10
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers	10
Off‐label and unlicensed medicine prescribing in university hospital paediatric wards in Finland: A prospective study	10
Issue Highlights	10
Spotlight commentary: De‐labelling the truth: Clearing the fog around antibiotic allergy labels	10
Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19	10
Issue Highlights	10
Drug shortages. Part 1. Definitions and harms	10
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants	10
The feasibility of pharmacokinetic‐based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial	10
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	10
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen	10
Oxcarbazepine was associated with risks of newly developed hypothyroxinaemia and impaired central set point of thyroid homeostasis in schizophrenia patients	10
Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction	10
Issue Information	10
Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: Editorial	10
Spotlight commentary: New Frontiers in pneumonia treatment	10
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B	10
Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis	10
Methodological issues in research on drug‐related admissions: A meta‐epidemiological review with focus on causality assessments	10
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease	10
	10
Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations	9